Celyad Oncology (LTS:0QFK) Total Assets : €12.18 Mil (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology Total Assets?

Celyad Oncology's Total Assets for the quarter that ended in Jun. 2023 was €12.18 Mil.

During the past 12 months, Celyad Oncology's average Total Assets Growth Rate was -85.60% per year. During the past 3 years, the average Total Assets Growth Rate was -47.60% per year. During the past 5 years, the average Total Assets Growth Rate was -21.90% per year. During the past 10 years, the average Total Assets Growth Rate was 7.40% per year.

During the past 12 years, Celyad Oncology's highest 3-Year average Total Assets Growth Rate was 75.90%. The lowest was -47.60%. And the median was 3.90%.

Total Assets is connected with ROA %. Celyad Oncology's annualized ROA % for the quarter that ended in Jun. 2023 was 0.00%. Total Assets is also linked to Revenue through Asset Turnover. Celyad Oncology's Asset Turnover for the quarter that ended in Jun. 2023 was 0.00.

Celyad Oncology Total Assets Historical Data

The historical data trend for Celyad Oncology's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Total Assets Chart

Celyad Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Assets

Get a 7-Day Free Trial

94.30

89.84

66.08

79.94

19.72

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Total Assets	Get a 7-Day Free Trial															79.94	69.22	63.14	19.72	12.18

Celyad Oncology Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Celyad Oncology's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	4.317	+	15.399
	=	19.72

Celyad Oncology's Total Assets for the quarter that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2023 )	+	Total Liabilities (Q: Jun. 2023 )
	=	1.019	+	11.159
	=	12.18

Celyad Oncology (LTS:0QFK) Total Assets Explanation

Total Assets is connected with ROA %.

Celyad Oncology's annualized ROA % for the quarter that ended in Jun. 2023 is

ROA %	=	Net Income (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	0	/	( (19.716	+	12.178)	/ 2 )
	=	0	/	15.947
	=	0.00 %

Note: The Net Income data used here is four times the quarterly (Jun. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Celyad Oncology's Asset Turnover for the quarter that ended in Jun. 2023 is

	Asset Turnover
=	Revenue (Q: Jun. 2023 )	/	( (Total Assets (Q: Dec. 2022 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
=	0	/	( (19.716	+	12.178)	/ 2 )
=	0	/	15.947
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Celyad Oncology Total Assets Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (LTS:0QFK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (LTS:0QFK) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

CYAD:Belgium

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (LTS:0QFK) Headlines

No Headlines